Summary
A 48-year-old defense contractor employee was denied a security clearance due to concerns under Guideline H (Drug Involvement) and Guideline E (Personal Conduct). The primary issue stemmed from the applicant's prolonged use of marijuana, which continued until November 2022. This raised significant doubts about his current reliability, trustworthiness, and judgment.
While the applicant essentially denied the personal conduct allegation, he failed to mitigate the security concerns related to drug involvement and substance misuse. Specifically, he did not provide sufficient verifiable proof of abstinence from drug use or disassociation from individuals involved in providing drugs.
Despite some mitigating conditions being considered, the applicant's inability to demonstrate a clear break from drug-related activities led to the denial of his security clearance. The decision emphasized the lack of evidence to resolve the concerns regarding his drug involvement and substance misuse.
Why the Applicant Was Denied
- The applicant failed to mitigate security concerns regarding drug involvement and substance misuse.
- He did not provide verifiable proof of abstinence from drug use or disassociation from drug-providing associates.
- The applicant's continued use of marijuana until November 2022 raised questions about his judgment and reliability.
Conditions Referenced
- AG ¶ 24raisedDrug Involvement and Substance Misuse
- AG ¶ 25(a)appliedSubstance Misuse
- AG ¶ 25(c)appliedIllegal Possession of a Controlled Substance
- AG ¶ 25(g)appliedExpressed Intent to Continue Drug Involvement
- AG ¶ 26(b)appliedAcknowledgment of Drug Involvement and Actions Taken to Overcome It
Key Rule Quoted
“Eligibility for a security clearance is denied.”
Procedural Posture
- SOR issuedApr 6, 2023
- Answer filedApr 26, 2023Applicant elected to have the case decided on the written record.
- Hearing held—Decision made based on written record.
- Decision dateJan 8, 2024
Cite For
- Failure to Provide Evidence of Abstinence From Drug Use
- Importance of Compliance with Federal Drug Laws in Security Clearance Determinations
- Evaluation of Drug Involvement Under Guideline H